desloratadine
DrugSCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
Other names: Clarinex, SCH 034117
NCT Number: NCT00779116
This was a randomized, open-label, 2-way cross-over study, comparing desloratadine RediTab 2.5 mg to a marketed chewable antihistamine oral medication (Zyrtec® 5 mg
Chewable Tablet). Subject preference for one product or the other was determined. Acceptability of product attributes (Taste and Feeling in the Mouth) was rated using a "smile" face scale.
Looking for future studies?
Notify Me6 year–11 year
All sexes
Interventional
Phase 4
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
Other names: Clarinex, SCH 034117
Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
Time frame: Following the second dose (8-10 minutes after the first dose)
A product preference questionnaire was completed after the administration of the second study drug. An interviewer instructed the subject "now that you have tasted the two tablets, show us which tablet you like more" and the subject then marked which tablet he/she preferred. If the subject had no preference, the response was recorded accordingly.
Organon and Co
Industry
A Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04644783
Allergies, Food Protein-Induced Enterocolitis Syndrome
Ann Arbor, Michigan, United States
View Trial DetailsNCT03213184
Allergic Asthma, Allergies
Baltimore, Maryland, United States
View Trial DetailsNCT00780403
Allergies, Hypersensitivity
View Trial DetailsNCT01613885
Allergies, Hypersensitivity
Stanford, California, United States
View Trial Details